MIRA (MIRA Pharmaceuticals, Inc.) Volume dana dhuwit perusahaan

MIRA Pharmaceuticals develops synthetic cannabinoid analogs, aiming for long-term dominance in the analgesics segment. The cash reserve level, as shown on the GURU.Markets chart, indicates that 0.01 is the current value of this metric. MIRA Pharmaceuticals is developing the MIRA-1a molecule to treat depression without addiction, currently undergoing clinical testing to confirm the safety of the drugs.
Rincian analitis perusahaan MIRA Pharmaceuticals

For MIRA Pharmaceuticals, which is developing an innovative line of non-opioid analgesics, liquidity balance is critical to sustaining its expansion phase. This indicator assesses the ratio of actual cash to operating expenses, while the cash position chart reveals excess reserves that may indicate inefficient capital management and a decline in overall return on investment.